224 Physiological properties of the body, including organ mass and volume, blood flow rate, plasma protein levels, and the abundance of enzyme and transporter expression, are mathematically described within the model
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Patrick RJ, Fenske NA, Messina JL
M., Schreiber, E., Fogel, H., et al
Hes authored over 200 publications and has been named among the top 1% of U.S
That matters because telogen effluvium often improves by addressing the trigger, while pattern hair loss usually needs longer-term management